A dementia genetic finding is classified as a variant of uncertain significance when a DNA change is found but evidence cannot show whether it causes disease. A VUS is not a dementia diagnosis or a reliable prediction of future dementia. Uncertainty does not mean the variant is probably harmful. It means the available population, laboratory, and family evidence is insufficient to place it on either side of the line.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the classification mean?
- What should not be decided from a VUS?
- Should relatives be tested?
- Can an uncertain result change?
- How does a VUS differ from other Alzheimer genetic results?
What does the classification mean?
Laboratories classify variants as benign, likely benign, uncertain, likely pathogenic, or pathogenic. These categories describe the strength of evidence connecting a variant to disease, according to the ACMG/AMP interpretation standard. A variant may remain uncertain because it is rare or lacks adequate population, functional, or family data.
The National Human Genome Research Institute explains that studying whether a variant tracks with disease among relatives can provide useful evidence. The uncertainty concerns that specific DNA change. It does not resolve whether someone's memory or thinking problems have another genetic or non-genetic explanation.
What should not be decided from a VUS?
A VUS should not be used to diagnose dementia, predict whether someone will develop it, or direct treatment and other clinical-management decisions. Those choices require evidence beyond an uncertain genetic finding.
In practical terms, a VUS alone should not be treated as proof that: The result still belongs in the medical record. It may become informative later, but its present limits should remain clear whenever clinicians or family members discuss it.
- Current symptoms have a genetic cause.
- An unaffected person will develop dementia.
- A relative inherited a meaningful dementia risk.
- Medical care should change because of the variant.
Should relatives be tested?
Relatives generally should not receive predictive testing for a family member's VUS. Whether they test positive or negative would not reliably establish their dementia risk. Targeted testing can sometimes serve a different purpose: helping a laboratory determine whether the variant appears alongside disease in a family.
That is evidence gathering, not predictive testing. A genetics professional can help identify which relatives, if any, might provide useful information. Testing decisions can affect several family members and create anxiety. Before sharing a report as evidence of inherited disease, confirm whether it contains a pathogenic finding, a risk-associated variant, or only a VUS.
Can an uncertain result change?
Yes. A laboratory may later reclassify a VUS as likely benign or likely pathogenic when new evidence becomes available. Laboratories often issue amended reports for reclassifications that could affect care.
Broader dementia panels, exome sequencing, and genome sequencing are more likely to uncover one or more uncertain variants. People from historically underrepresented populations may encounter greater uncertainty because available reference genomic data are less extensive. To keep the result from becoming an abandoned report:.
- Keep the complete report and the laboratory's contact information.
- Ask the ordering clinician who will receive amended reports.
- Keep contact details current with the clinic or laboratory.
- Periodically ask whether the original laboratory has updated the classification.
- Seek reinterpretation before using an old result for a new family decision.
How does a VUS differ from other Alzheimer genetic results?
The wording on the report matters. An APOE-e4 result indicates increased Alzheimer disease risk, but it does not diagnose the disease. By contrast, pathogenic variants in APP, PSEN1, or PSEN2 can establish autosomal-dominant early-onset familial Alzheimer disease, as explained by GeneReviews. A VUS in one of those genes is not equivalent to a pathogenic variant.
The gene's importance does not override the variant's uncertain classification. Genetic counseling is appropriate before dementia testing and when results arrive. The Alzheimer's Association notes that interpretation may affect relatives and raise concerns involving anxiety, discrimination, insurance, and long-term care. Bring the full laboratory report—not a shortened patient-portal summary—to that discussion.
